Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives

被引：17

作者：

Matsumoto, Koji ^{[1
]}

Onda, Takashi ^{[2
]}

Yaegashi, Nobuo ^{[3
]}

机构：

[1] Hyogo Canc Ctr, Div Med Oncol, Akashi, Hyogo, Japan

[2] Kitasato Univ, Div Gynecol & Obstet, Sagamihara, Kanagawa 228, Japan

[3] Tohoku Univ, Div Gynecol & Obstet, Sendai, Miyagi 980, Japan

来源：

JAPANESE JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 45卷 / 05期

关键词：

chemo-gynecology; gynecol-med; molecular Dx; PEGYLATED LIPOSOMAL DOXORUBICIN; PHASE-III TRIAL; DOUBLE-BLIND; BEVACIZUMAB; THERAPY; CHEMOTHERAPY; CARBOPLATIN; COMBINATION; PROGRESSION; PACLITAXEL;

D O I：

10.1093/jjco/hyv014

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Several 'lines of therapy' that utilize cytotoxic agents and are driven by platinum-free intervals are the current standard of care for patients with recurrent ovarian cancer. For patients with platinum-resistant disease, single agent chemotherapy (pegylated liposomal doxorubicin, topotecan, gemcitabine or weekly paclitaxel) is the standard of care. For patients with platinum-sensitive disease, combination chemotherapy (carboplatin plus paclitaxel, pegylated liposomal doxorubicin or gemcitabine) is the standard of care. In addition, antiangiogenic therapy using bevacizumab is an established option. Future directions could include 'lines of therapy' with biologic agents driven by specific biologic targets. Data from antiangiogenic agents (trebananib, pazopanib and cediranib), antifolate drugs (farletuzumab and vintafolide), poly(ADP-ribose) polymerase inhibitors (olaparib and veliparib), mTOR inhibitors (everolimus and temsirolimus) and immune editing agents (nivolumab) have been summarized in this review.

引用

页码：408 / 410

页数：3

共 23 条

[1] OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [J].

Aghajanian, Carol ;

Blank, Stephanie V. ;

Goff, Barbara A. ;

Judson, Patricia L. ;

Teneriello, Michael G. ;

Husain, Amreen ;

Sovak, Mika A. ;

Yi, Jing ;

Nycum, Lawrence R. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) :2039-2045

[2] Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial [J].

Bennouna, Jaafar ;

Sastre, Javier ;

Arnold, Dirk ;

Osterlund, Pia ;

Greil, Richard ;

Van Cutsem, Eric ;

von Moos, Roger ;

Maria Vieitez, Jose ;

Bouche, Olivier ;

Borg, Christophe ;

Steffens, Claus-Christoph ;

Alonso-Orduna, Vicente ;

Schlichting, Christoph ;

Reyes-Rivera, Irmarie ;

Bendahmane, Belguendouz ;

Andre, Thierry ;

Kubicka, Stefan .

LANCET ONCOLOGY, 2013, 14 (01) :29-37

[3] Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer [J].

Burger, Robert A. ;

Brady, Mark F. ;

Bookman, Michael A. ;

Fleming, Gini F. ;

Monk, Bradley J. ;

Huang, Helen ;

Mannel, Robert S. ;

Homesley, Howard D. ;

Fowler, Jeffrey ;

Greer, Benjamin E. ;

Boente, Matthew ;

Birrer, Michael J. ;

Liang, Sharon X. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (26) :2473-2483

[4] The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy [J].

Hanker, L. C. ;

Loibl, S. ;

Burchardi, N. ;

Pfisterer, J. ;

Meier, W. ;

Pujade-Lauraine, E. ;

Ray-Coquard, I. ;

Sehouli, J. ;

Harter, P. ;

du Bois, A. .

ANNALS OF ONCOLOGY, 2012, 23 (10) :2605-2612

[5] Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial [J].

Katsumata, Noriyuki ;

Yasuda, Makoto ;

Takahashi, Fumiaki ;

Isonishi, Seiji ;

Jobo, Toshiko ;

Aoki, Doisuke ;

Tsuda, Hiroshi ;

Sugiyama, Toru ;

Kodama, Shoji ;

Kimura, Eizo ;

Ochiai, Kazunori ;

Noda, Kiichiro .

LANCET, 2009, 374 (9698) :1331-1338

[6]

Kaufman B., 2014, J CLIN ONCOL

[7] Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer [J].

Ledermann, Jonathan ;

Harter, Philipp ;

Gourley, Charlie ;

Friedlander, Michael ;

Vergote, Ignace ;

Rustin, Gordon ;

Scott, Clare ;

Meier, Werner ;

Shapira-Frommer, Ronnie ;

Safra, Tamar ;

Matei, Daniela ;

Macpherson, Euan ;

Watkins, Claire ;

Carmichael, James ;

Matulonis, Ursula .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (15) :1382-1392

[8] Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) [J].

Lortholary, A. ;

Largillier, R. ;

Weber, B. ;

Gladieff, L. ;

Alexandre, J. ;

Durando, X. ;

Slama, B. ;

Dauba, J. ;

Paraiso, D. ;

Pujade-Lauraine, E. .

ANNALS OF ONCOLOGY, 2012, 23 (02) :346-352

[9] 2ND-LINE PLATINUM THERAPY IN PATIENTS WITH OVARIAN-CANCER PREVIOUSLY TREATED WITH CISPLATIN [J].

MARKMAN, M ;

ROTHMAN, R ;

HAKES, T ;

REICHMAN, B ;

HOSKINS, W ;

RUBIN, S ;

JONES, W ;

ALMADRONES, L ;

LEWIS, JL .

JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (03) :389-393

[10] Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR) [J].

Meier, Werner ;

du Bois, Andreas ;

Reuss, Alexander ;

Kuhn, Walther ;

Olbricht, Sigrid ;

Gropp, Martina ;

Richter, Barbara ;

Lueck, Hans-Joachim ;

Kimmig, Rainer ;

Pfisterer, Jacobus .

GYNECOLOGIC ONCOLOGY, 2009, 114 (02) :199-205

← 1 2 3 →